Antigenic cancer cells grow progressively in immune hosts without evidence for T cell exhaustion or systemic anergy

Journal of Experimental Medicine

Volumn 186, Issue 2, 1997, Pages 229-238

  Wick, Maresa ^a   Dubey, Purnima ^a   Koeppen, Hartmut ^a   Siegel, Christopher T ^a   Fields, Patrick E ^a   Chen, Lieping ^b   Bluestone, Jeffrey A ^a   Schreiber, Hans ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER TRANSPLANTATION; CELL GROWTH; CLONAL ANERGY; CONTROLLED STUDY; FEMALE; GRAFT REJECTION; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE; TUMOR IMMUNOLOGY;

ANIMALS; GRAFT REJECTION; HISTOCOMPATIBILITY ANTIGENS CLASS I; IMMUNE TOLERANCE; IMMUNIZATION; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, INBRED DBA; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; RECEPTORS, ANTIGEN, T-CELL; SKIN TRANSPLANTATION; T-LYMPHOCYTES; TRANSFECTION;

EID: 0030807565     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.186.2.229     Document Type: Article

References (37)

1. Chen, L., P.S. Linsley, and K.E. Hellström. 1993. Costimulation of T cells for tumor immunity. Immunol. Today. 14: 483-486.
2. O'Connell, J., G.C. O'Sullivan, J.K. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J. Exp. Med. 184: 1075-1082.
3. Strand, S., W.J. Hofmann, H. Hug, M. Müller, G. Otto, D. Strand, S.M. Mariani, W. Stremmel, P.H. Krammer, and P.R. Galle. 1996. Lymphocyte apoptosis induced by CD95 (APO-1/FAS) ligand-expressing tumor cells - a mechanism of immune evasion? Nature Med. 2:1361-1370.
4. Hahne, M., D. Rimoldi, M. Schröter, P. Romero, M. Schreier, L.E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, J.-C. Cerottini, and J. Tschopp. 1996. Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape. Science (Wash. DC). 274:1363-1366.
5. Ranges, G.E., I.S. Figari, T. Espevik, and M.A. Palladino. 1987. Inhibition of cytotoxic T cell development by transforming growth factor β and reversal by recombinant tumor necrosis factor α. J. Exp. Med. 166:991-998.
6. Torre-Amione, G., R.D. Beauchamp, H. Koeppen, B.H. Park, H. Schreiber, H.L. Moses, and D.A. Rowley. 1990. A highly immunogenic tumor transfected with a murine TGF-β cDNA escapes immune surveillance. Proc. Natl. Acad. Sci. USA. 87:1468-1490.
7. Cousins, S.W., M.M. McCabe, D. Danielpour, and J.W. Streilein. 1991. Identification of transforming growth factor-beta as an immunosuppressive factor in aqueous humor. Invest. Opthalmol. Vis. Sci. 32:2201-2211.
8. Singh, S., S.R. Ross, M. Acena, D.A. Rowley, and H. Schreiber. 1992. Stroma is critical for preventing or permitting immunological destruction of antigenic cancer cells. J. Exp. Med. 175:139-146.
9. Schreiber, H. 1993. Tumor immunology. In Fundamental Immunology. Third edition. W.E. Paul, editor. Raven Press, Ltd., New York. 1143-1178.
10. O'Reilly, M.S., L. Holmgren, Y. Shing, C. Chen, R.A. Rosenthal, M. Moses, W.S. Lane, Y. Cao, E.H. Sage, and J. Folkman. 1994. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell. 79:315-328.
11. O'Reilly, M.S., L. Holmgrem, C. Chen, and J. Folkman. 1996. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med. 2:689-692.
12. Perdrizet, G.A., S.R. Ross, H.J. Stauss, S. Singh, H. Koeppen, and H. Schreiber. 1990. Animals bearing malignant grafts reject normal grafts that express through gene transfer the same antigen. J. Exp. Med. 171:1205-1220.
13. Sha, W.C., C.A. Nelson, R.D. Newberry, D.M. Kranz, J.H. Russell, and D.Y. Loh. 1988. Selective expression of an antigen receptor on CD8-bearing T lymphocytes in transgenic mice. Nature (Lond.). 335:271-274.
14. + cytotoxic T lymphocytes in association with a class I MHC protein. Cell. 69:989-998.
15. + T-cell clone. Proc. Natl. Acad. Sci. USA. 90:11272-11276.
16. Kranz, D.M., S. Tonegawa, and H.N. Eisen. 1984. Attachment of an anti-receptor antibody to non-target cells renders them susceptible to lysis by a clone of cytotoxic T lymphocytes. Proc. Natl. Acad. Sci. USA. 81:7922-7926.
17. Ward, P.L., H. Koeppen, T. Hurteau, and H. Schreiber. 1989. Tumor antigens defined by cloned immunological probes are highly polymorphic and are not detected on autologous normal cells. J. Exp. Med. 170:217-232.
18. Li, Y., K.E. Hellström, S.A. Newby, and L. Chen. 1996. Co-stimulation by CD48 and B7-1 induces immunity against poorly immunogenic tumors. J. Exp. Med. 183:639-644.
19. Loss, G.E., Jr., C.G. Elias, P.E. Fields, R.K. Ribaudo, M. McKisic, and A.J. Sant. 1993. Major histocompatibility complex class II-restricted presentation of an internally synthesized antigen displays cell-type variability and segregates from the exogenous class II and endogenous class I presentation pathways. J. Exp. Med. 178:73-85.
20. Billingham, R.E., and P.B. Medawar. 1951. The technique of free skin grafting in mammals. J. Exp. Biol. 28:385-402.
21. Seung, L.P., D.A. Rowley, P. Dubey, and H. Schreiber. 1995. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc. Natl. Acad. Sci. USA. 92:6254-6258.
22. d antigen, the products of a third polymorphic locus of the mouse major histocompatibility complex. J. Immunol. 125: 2473-2477.
23. Cobbold, S.P., A. Jayasuriya, A. Nash, T.D. Prospero, and H. Waldmann. 1984. Therapy with monoclonal antibodies by elimination of T cell subsets in vivo. Nature (Lond.). 312: 548-551.
24. Dialynas, D.P., D.B. Wilde, P. Marrack, A. Pierres, K.A. Wall, W. Havran, G. Otten, M.R. Loken, M. Pierres, J. Kappler, and F.W. Fitch. 1983. Characterization of the murine antigenic determinant, designated L3T4a, recognized by monoclonal antibody GK1.5: expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity. Immunol. Rev. 74:29-56.
25. Koeppen, H., M. Acena, A. Drolet, D.A. Rowley, and H. Schreiber. 1993. Tumors with reduced expression of a cytotoxic T lymphocyte recognized antigen lack immunogenicity but retain sensitivity to lysis by cytotoxic T lymphocytes. Eur. J. Immunol. 23:2770-2776.
26. + T cell proliferation in the class I MHC-restricted 2C TCR-transgenic mouse. J. Immunol. 156:2036-2044.
27. Sykulev, Y., A. Brunmark, T.J. Tsomides, S. Kageyama, M. Jackson, P.A. Peterson, and H.N. Eisen. 1994. High-affinity reactions between antigen-specific T-cell receptors and peptides associated with allogencic and syngeneic major histocompatibility complex class I proteins. Proc. Natl. Acad. Sci. USA. 91:11487-11491.
28. Wu, M.X., T.J. Tsomides, and H.N. Eisen. 1995. Tissue distribution of natural peptides derived from a ubiquitous dehydrogenase, including a novel liver-specific peptide that demonstrates the pronounced specificity of low affinity T cell reactions. J. Immunol. 154:4495-4502.
29. Moskophidis, D., F. Lechner, H. Pircher, and R.M. Zinkernagel. 1993. Virus persistence in acutely infected immuno-competent mice by exhaustion of antiviral cytotoxic effector T cells. Nature (Lond.). 362:758-761.
30. + T cells. Eur. J. Immunol. 23:3306-3311.
31. Mizoguchi, H., J.J. O'Shea, D.L. Longo, C.M. Loeffler, D.W. McVicar, and A.C. Ochoa. 1992. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science (Wash. DC). 258:1795-1798.
32. Nakagomi, H., M. Petersson, I. Magnusson, C. Juhlin, M. Matsuda, H. Mellstedt, J.L. Taupin, E. Vivier, P. Anderson, and R. Kiessling. 1993. Decreased expression of the signal-transducing zeta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 53: 5610-5612.
33. Matsuda, M., M. Petersson, R. Lenkei, J.L. Taupin, I. Magnusson, H. Mellstedt, P. Anderson, and R. Kiessling. 1995. Alterations in the signal-transducing molecules of T cells and NK cells in colorectal tumor-infiltrating, gut mucosal and peripheral lymphocytes: correlation with the stage of the disease. Int. J. Cancer 61:765-772.
34. Sperling, A.I., J.A. Auger, B.D. Ehst, I.C. Rulifson, C.B. Thompson, and J.A. Bluestone. 1996. CD28/B7 interactions deliver a unique signal to naive T cells that regulates cell survival but not early proliferation. J. Immunol. 157:3909-3917.
35. Chen, L., S. Ashe, W.A. Brady, I. Hellström, K.E. Hellström, J.A. Ledbetter, P. McGowan, and P.S. Linsley. 1992. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 71:1093-1102.
36. + T cells by B7-transfected melanoma cells. Science (Wash. DC). 259:368-370.
37. Gajewski, T.F., and F.W. Fitch. 1990. Anti-proliferative effect of IFN-gamma in immune regulation. IV. Murine CTL clones produce IL-3 and GM-CSF, the activity of which is masked by the inhibitory action of secreted IFN-gamma. J. Immunol. 144:548-556.